Detalle Publicación


Mid-Term Results of Transcatheter Arterial Embolization for Adhesive Capsulitis Resistant to Conservative Treatment

Autores: Martinez, A. M. F. (Autor de correspondencia); Baldi, S. ; Alonso Burgos, Alberto; Lopez, R.; Vallejo-Pascual, M. E. ; Marcos, M. T. C.; Alonso, D. R.; Prieto, J. R. ; Mauriz, J. L.
ISSN: 0174-1551
Volumen: 44
Número: 3
Páginas: 443 - 451
Fecha de publicación: 2021
Purpose To evaluate the mid-term clinical outcomes of transcatheter arterial embolization (TAE) for adhesive capsulitis (AC) resistant to medical treatments. Materials and Methods This is a prospective analysis performed between February 2016 and February 2020. Inclusion criteria for TAE were shoulder pain, restriction of movement and no response to conservative treatment for at least 3 months. Demographic variables, risk factors, technical aspects, adverse events, changes by visual analogue scale (VAS) for pain and physical examination before and after TAE were assessed. Results This study included 40 patients with AC (35 women and 5 men; mean age 50 +/- 9 years old). Abnormal vessels were observed in 31/40 (77.5%) procedures. As embolic agent, imipenem/cilastatin was used. The mean follow-up was 21.2 +/- 10.5 months. Significant differences were obtained in terms of pain reduction before and 6 months after TAE with the median visual analogue scale (VAS) of 8 vs. 0.5, P = 0.0001. Substantial differences were found regarding mobility in flexion and abduction before and 6 months after embolization, respectively (79.5 degrees +/- 18.5 degrees vs. 133 degrees +/- 24.5 degrees, P = 0.0001; 72.4 degrees +/- 18.8 degrees vs. 129.7 degrees +/- 27.9 degrees, P = 0.0001). No complications occurred. Complete recovery was obtained in 37/40 (92.5%) patients and partial recovery in 2/40 (5%). No clinical recurrence appeared. Conclusions Clinical results of transcatheter arterial embolization with imipenem/cilastatin are effective and stable in the mid-term follow-up for patients presenting with AC resistant to conservative treatments.